Back to Search
Start Over
Peripheral T-cell lymphomas as fingolimod-associated lymphoproliferative disorder for patients with multiple sclerosis - case report with literature review.
- Source :
- Leukemia & Lymphoma; Apr2020, Vol. 61 Issue 4, p959-962, 4p
- Publication Year :
- 2020
-
Abstract
- Over the past 25 years, the application of immunomodulating and immunosuppressive agents in the treatment of multiple sclerosis (MS), an autoimmune demyelinating and neurodegenerative disease, has led to improvements in clinical outcomes [[1]]. The induction of diffuse large B cell lymphoma (DLBCL) by methotrexate in arthritis patients and the induction of hepatosplenic T-cell lymphoma by infliximab (anti-human tumor necrosis factor-alfa antibody) in patients with inflammatory bowel diseases are typical examples [[14]]. Patients with primary cutaneous CD30-positive ALCL generally have a good prognosis, and three patients with cutaneous CD30-positive ALCL (no. 2-4) remained alive for 2-18 months (Table 1). Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod. [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 61
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 142373013
- Full Text :
- https://doi.org/10.1080/10428194.2019.1691197